vTv Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VTVT research report →
About the company
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes.
- CEO
- Paul J. Sekhri
- IPO
- 2015
- Employees
- 23
- HQ
- High Point, NC, US
Price Chart
- Market Cap
- $92.65M
- P/E
- 1770.00
- P/S
- 2.51
- P/B
- 3.31
- EV/EBITDA
- 7.60
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -8.26%
- Net Margin
- 6.11%
- ROE
- 3.96%
- ROIC
- -3.31%
- Revenue
- $0 · -100.00%
- Net Income
- $-26,974,000 · -46.11%
- EPS
- $-3.20 · 0.00%
- Op Income
- $-32,808,000
- FCF YoY
- 0.21%
- 52W High
- $44.00
- 52W Low
- $14.00
- 50D MA
- $33.68
- 200D MA
- $32.27
- Beta
- 0.27
- Avg Volume
- 53.19K
Get TickerSpark's AI analysis on VTVT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | BAKER BROS. ADVISORS LP | other | 6,000 |
| Jun 26, 26 | SPIEGELMAN DANIEL K | other | 6,000 |
| Jun 26, 26 | AKKARAJU SRINIVAS | other | 6,000 |
| Jun 26, 26 | Al-Marzooqi Fahed | other | 6,000 |
| Jun 26, 26 | Phillips Anne M. | other | 6,000 |
| Feb 17, 26 | Tung Michael Stephen | other | 44,969 |
| Feb 17, 26 | SEKHRI PAUL J | other | 140,000 |
| Sep 22, 25 | AKKARAJU SRINIVAS | other | 983,214 |
| Sep 22, 25 | AKKARAJU SRINIVAS | other | 877,214 |
| Sep 22, 25 | AKKARAJU SRINIVAS | other | 106,000 |
Our VTVT coverage
Recent articles, reports, and earnings notes.
Want a deeper read on VTVT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.